Assignee
HELSINN HEALTHCARE SA
CH·61 granted patents·28 pending applications·185 citations·filing 1995–2025
Top patents by PatentIndex Score
89 records- 0197US10828297B2Compositions and methods for treating centrally mediated nausea and vomitingHELSINN HEALTHCARE SA·Filed 2018·Granted Nov 10, 2020·16 cites·23 claims
- 0292US8951969B2Compositions and methods for treating centrally mediated nausea and vomitingHELSINN HEALTHCARE SA·Filed 2013·Granted Feb 10, 2015·7 cites·11 claims
- 0392US8598219B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2013·Granted Dec 3, 2013·6 cites·8 claims
- 0492US7960424B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2006·Granted Jun 14, 2011·16 cites·6 claims
- 0592US7947725B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2006·Granted May 24, 2011·15 cites·2 claims
- 0692US7947724B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2005·Granted May 24, 2011·16 cites·14 claims
- 0791US8729094B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2013·Granted May 20, 2014·5 cites·30 claims
- 0890US2026027138A1Physiologically balanced injectable formulations of fosnetupitantHELSINN HEALTHCARE SA·Filed 2025·Application pending·0 cites
- 0989US10676440B2Crystalline forms of an NK-1 antagonistHELSINN HEALTHCARE SA·Filed 2019·Granted Jun 9, 2020·4 cites·13 claims
- 1089US10208073B2Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulatorHELSINN HEALTHCARE SA·Filed 2018·Granted Feb 19, 2019·2 cites·13 claims
- 1189US9403867B2Methods of producing anamorelin hydrochloride having controlled chloride contentHELSINN HEALTHCARE SA·Filed 2014·Granted Aug 2, 2016·9 cites·19 claims
- 1289US9186357B2Compositions and methods for treating centrally mediated nausea and vomitingHELSINN HEALTHCARE SA·Filed 2013·Granted Nov 17, 2015·4 cites·62 claims
- 1388US9125905B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2015·Granted Sep 8, 2015·2 cites·9 claims
- 1487US10961195B2Crystalline forms of an NK-1 antagonistHELSINN HEALTHCARE SA·Filed 2020·Granted Mar 30, 2021·2 cites·7 claims
- 1587US9951016B2Crystalline forms of an NK-1 antagonistHELSINN HEALTHCARE SA·Filed 2015·Granted Apr 24, 2018·7 cites·13 claims
- 1687US8598218B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2013·Granted Dec 3, 2013·6 cites·11 claims
- 1787US2025235473A1Physiologically balanced injectable formulations of fosnetupitantHELSINN HEALTHCARE SA·Filed 2024·Application pending·0 cites
- 1886US9173942B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2013·Granted Nov 3, 2015·2 cites·19 claims
- 1985US10233154B2Crystalline forms of an NK-1 antagonistHELSINN HEALTHCARE SA·Filed 2018·Granted Mar 19, 2019·5 cites·7 claims
- 2085US9981002B2Methods of producing anamorelin hydrochloride having controlled chloride contentHELSINN HEALTHCARE SA·Filed 2016·Granted May 29, 2018·3 cites·19 claims
- 2185US9956261B2Methods of producing anamorelin hydrochloride having controlled chloride contentHELSINN HEALTHCARE SA·Filed 2016·Granted May 1, 2018·3 cites·18 claims
- 2285US9872883B2Methods of producing anamorelin hydrochloride having controlled chloride contentHELSINN HEALTHCARE SA·Filed 2016·Granted Jan 23, 2018·3 cites·22 claims
- 2385US9403772B24-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulatorHELSINN HEALTHCARE SA·Filed 2012·Granted Aug 2, 2016·4 cites·14 claims
- 2484US11529362B2Physiologically balanced injectable formulations of fosnetupitantHELSINN HEALTHCARE SA·Filed 2020·Granted Dec 20, 2022·1 cites·28 claims
- 2583US12208109B2Physiologically balanced injectable formulations of fosnetupitantHELSINN HEALTHCARE SA·Filed 2022·Granted Jan 28, 2025·0 cites·23 claims
- 2683US10278964B2Medical treatments based on anamorelinHELSINN HEALTHCARE SA·Filed 2017·Granted May 7, 2019·4 cites·26 claims
- 2783US9546157B2Asymmetric piperidinyl-substituted ureas as medicinesHELSINN HEALTHCARE SA·Filed 2015·Granted Jan 17, 2017·4 cites·38 claims
- 2883US9066980B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2013·Granted Jun 30, 2015·3 cites·16 claims
- 2982US10624911B2Physiologically balanced injectable formulations of fosnetupitantHELSINN HEALTHCARE SA·Filed 2017·Granted Apr 21, 2020·2 cites·21 claims
- 3081US12440485B2Centrally-active ghrelin agonist and medical uses thereofHELSINN HEALTHCARE SA·Filed 2024·Granted Oct 14, 2025·0 cites·28 claims
- 3179US12071421B2Process for the synthesis of substituted chloromethyl dialkylphosphatesHELSINN HEALTHCARE SA·Filed 2022·Granted Aug 27, 2024·0 cites·3 claims
- 3279US10577384B2Substituted asymmetric ureas as modulators of ghrelin receptor activityHELSINN HEALTHCARE SA·Filed 2018·Granted Mar 3, 2020·2 cites·15 claims
- 3379US10300105B2Methods of producing anamorelin hydrochloride having controlled chloride contentHELSINN HEALTHCARE SA·Filed 2018·Granted May 28, 2019·1 cites·29 claims
- 3479US2024024303A1Medical Treatments Based on AnamorelinHELSINN HEALTHCARE SA·Filed 2023·Application pending·0 cites
- 3578US12005056B2Centrally-active ghrelin agonist and medical uses thereofHELSINN HEALTHCARE SA·Filed 2019·Granted Jun 11, 2024·2 cites·22 claims
- 3678US9926337B2Substituted asymmetric ureas as modulators of ghrelin receptor activityHELSINN HEALTHCARE SA·Filed 2016·Granted Mar 27, 2018·2 cites·19 claims
- 3777US2025367181A1Centrally-Active Ghrelin Agonist and Medical Uses ThereofHELSINN HEALTHCARE SA·Filed 2025·Application pending·0 cites
- 3876US10407390B2Asymmetric ureas and medical uses thereofHELSINN HEALTHCARE SA·Filed 2017·Granted Sep 10, 2019·1 cites·3 claims
- 3975US11559523B2Compositions and methods for treating centrally mediated nausea and vomitingHELSINN HEALTHCARE SA·Filed 2020·Granted Jan 24, 2023·0 cites·18 claims
- 4075US11312698B2Fosnetupitant chloride hydrochloride having improved stabilityHELSINN HEALTHCARE SA·Filed 2020·Granted Apr 26, 2022·0 cites·12 claims
- 4175US9308266B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2013·Granted Apr 12, 2016·1 cites·1 claims
- 4272US11723902B2Medical treatments based on anamorelinHELSINN HEALTHCARE SA·Filed 2020·Granted Aug 15, 2023·0 cites·12 claims
- 4371US12071406B2Crystalline forms of an NK-1 antagonistHELSINN HEALTHCARE SA·Filed 2021·Granted Aug 27, 2024·0 cites·6 claims
- 4471US10905737B2Methods of producing anamorelin hydrochloride having controlled chloride contentHELSINN HEALTHCARE SA·Filed 2020·Granted Feb 2, 2021·0 cites·20 claims
- 4571US10717721B2Substituted piperaziniums for the treatment of emesisHELSINN HEALTHCARE SA·Filed 2018·Granted Jul 21, 2020·0 cites·2 claims
- 4671US10576122B2Methods of producing anamorelin hydrochloride having controlled chloride contentHELSINN HEALTHCARE SA·Filed 2019·Granted Mar 3, 2020·0 cites·25 claims
- 4771US9271975B2Compositions and methods for treating centrally mediated nausea and vomitingHELSINN HEALTHCARE SA·Filed 2013·Granted Mar 1, 2016·0 cites·12 claims
- 4870US11884646B2Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, methods of preparation, and uses thereofHELSINN HEALTHCARE SA·Filed 2022·Granted Jan 30, 2024·0 cites·27 claims
- 4970US2018193262A1Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2017·Application pending·0 cites
- 5069US9457021B1Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2016·Granted Oct 4, 2016·0 cites·20 claims
Showing the top 50 of 89 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when HELSINN HEALTHCARE SA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →